SCHEMBL26640280

SCHEMBL26640280

CN(C)CC(=O)Nc1ccc(N)cn1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.48
PTGS1 P23219 3/20 0.47
TDP1 Q9NUW8 1/20 0.44
MAPT P10636 2/20 0.43
ABL1 P00519 1/20 0.43
PARP1 P09874 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
TLR9 Q9NR96 2/20 0.42
TLR8 Q9NR97 2/20 0.42
TLR7 Q9NYK1 2/20 0.42
NPC1 O15118 2/20 0.41
MKNK1 Q9BUB5 1/20 0.41
GLA P06280 1/20 0.40
MAPK1 P28482 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
DEGS1 O15121 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30648774 1.00 RAB9A (0.48) RAB9APTGS1TDP1MAPTABL1
SCHEMBL15743907 0.83 RAB9A (0.67) RAB9AMAPTSMN1; SMN2NPC1L3MBTL1
SCHEMBL30753588 0.82 HSD17B10 (0.54) RAB9APTGS1TDP1MAPTSMN1; SMN2
SCHEMBL22557436 0.82 HSD17B10 (0.54) RAB9APTGS1TDP1MAPTSMN1; SMN2
SCHEMBL29395250 0.82 TSHR (0.57) RAB9APTGS1TDP1SMN1; SMN2NPC1
SCHEMBL6611739 0.81 RAB9A (0.62) RAB9AMAPTSMN1; SMN2NPC1MAPK1
SCHEMBL15986882 0.81 PTGS1 (0.42) RAB9APTGS1TDP1NPC1L3MBTL1
SCHEMBL22580173 0.80 PTGS1 (0.51) RAB9APTGS1TDP1MAPTSMN1; SMN2
SCHEMBL30753602 0.80 PTGS1 (0.51) RAB9APTGS1TDP1MAPTSMN1; SMN2
SCHEMBL13662156 0.80 DEGS1 (0.49) RAB9ATDP1MAPTABL1PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4522618-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS Merck Patent GmbH (DE) 2025-03-19 EP disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 US disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 US disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 US disclosed
WO-2023220541-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS MERCK PATENT GMBH (DE) 2023-11-16 WO disclosed
WO-2023220541-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS MERCK PATENT GMBH (DE) 2023-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS PDXK, DTYMK, HIPK1 RAB9A 2076/4885PTGS1 791/4885TDP1 462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.